The Next Alzheimer’s Breakthrough Will Take More Than Just Science
WIRED • • health
Key Points:
- Alzheimer’s research is progressing with new treatments like Donanemab and Lecanemab that can remove amyloid deposits from the brain and slow cognitive decline in patients, though they do not stop the disease entirely.
- John Hardy, a leading Alzheimer’s researcher, emphasized that alongside drug development, better diagnosis through genetics and biomarkers and increased political commitment are essential to improve treatment outcomes.
- Early Alzheimer's diagnosis remains a challenge, with many patients receiving a general dementia diagnosis rather than a specific Alzheimer’s diagnosis, highlighting the need for investment in dementia services.
- While the amyloid theory remains debated, recent drug trials, including those for Gantenerumab, show promise in delaying symptoms when administered at higher doses over longer periods.
- Hardy calls for continued scientific innovation to develop more effective drugs, earlier diagnostic methods, and political will to support dementia care infrastructure globally.
